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SUMMARY. Lamivudine has demonstrated efficacy for the
treatment of hepatitis B e antigen-negative chronic hepatitis
B (e-CHB). However, treatment withdrawal after 1 year has
been associated with a high rate of relapse while long-term
treatment is associated with increasing risks of drug resist-
ance. We report our treatment experience of 50 Chinese-
Canadian patients with e-CHB. All patients received lami-
vudine for 2 years. Treatment was withdrawn at month 24
in patients who had undetectable hepatitis B virus (HBV)
DNA by PCR and normal aminotransferases during the
second year of therapy. All patients had HBV genotype B or
C. Biochemical response at months 6, 12 and 24 was 74%,
71% and 66%, respectively. HBV DNA was undetectable at
months 6, 12 and 24 by hybrid capture and PCR assays in
100%, 92% and 86%; and 94%, 88% and 74% patients,
respectively. The cumulative rates of genotypic resistance
(GR) after 1 and 2 years were 15% and 25%, respectively.
Four (44%) patients with GR experienced a hepatitis flare.
The probability of clinical and virological relapse 6, 12, and
18 months after treatment withdrawal were 12% and 30%,
18% and 50%, and 30% and 50%, respectively. Reinstitu-
tion of lamivudine resulted in prompt virological and
biochemical responses. Our study demonstrates that a
sustained response can be achieved after a 2-year course of
lamivudine in a subset of patients with e-CHB.
Keywords: HBV core promoter mutation, HBV precore
mutation, hepatitis B virus genotypes, lamivudine resistance.
INTRODUCTION
Hepatitis B e antigen-negative chronic hepatitis B (e-CHB) is
characterized by the absence of hepatitis B e antigen
(HBeAg), detectable serum hepatitis B virus (HBV) DNA by
non-PCR-based assays, and liver necroinflammation
(abnormal aminotransferases, histological evidence of
chronic hepatitis with/without cirrhosis) [1]. This condition
has been reported worldwide but is most commonly seen in
Mediterranean countries, the Middle East and East Asia
[2–9]. In a recent report from Hong Kong, over 20% of
patients with chronic HBV infection seen in a university
teaching hospital hepatitis clinic were found to have e-CHB
[10]. Most patients with e-CHB harbour variants of HBV
that contain mutations in the precore or core promoter
regions of the HBV genome that abolish or down-regulate
the production of HBeAg. The precore stop codon mutation
(G1896A) has been found in over 90% of Europeans but
only in <50% of Chinese patients with e-CHB [2,3,10]. The
prevalence of the dual mutation (A1762T + G1764A) in the
core promoter region among patients with e-CHB is less
clear [11]. The vast majority of European patients with
e-CHB are infected with HBV genotype D but most Asian
patients with e-CHB are infected with HBV genotypes B and
C [12,13].
Lamivudine is effective in the treatment of HBeAg-positive
as well as HBeAg-negative chronic hepatitis B [14–20].
Several studies of patients with e-CHB have reported re-
sponse rates, defined as undetectable HBV DNA by solution
hybridization or branched DNA assays and normal alanine
aminotransferase (ALT), of 60–70% at the end of 1 year of
lamivudine treatment [16–20]. However, withdrawal
of lamivudine therapy is associated with a relapse rate of
approximately 90% within 6 months of treatment discon-
tinuation (abnormal ALT and re-detection of serum HBV
DNA using non-PCR-based assays) when lamivudine was
given for only 1 year [16,21]. In attempts to increase the
sustained response rates, many investigators have explored
extended or indefinite lamivudine treatment for patients with
e-CHB. However, long-term therapy is associated with
increasing rates of virological breakthrough, from 10–30%
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at 1 year [15,18,19,22,23] to 50% at 2 years [22,24]
because of selection of mutations in the YMDD motif of the
HBV DNA polymerase gene (rtM204V/I ± rtL180M). A re-
cent study suggested that all patients with virological
breakthrough developed biochemical relapse within
24 months [24]. These data indicate that the initial benefit
of lamivudine treatment may ultimately be negated in pa-
tients who developed lamivudine resistance. Thus, it is
important to determine if sustained off-treatment response
can be achieved after a 2-year course of therapy.
We report our experience with lamivudine treatment in
Chinese adults with e-CHB. The aims of this analysis were to
determine: (i) the virological and biochemical response to a
2-year course of lamivudine treatment in Chinese adults
with e-CHB; (ii) the rate of virological and biochemical
breakthrough during lamivudine therapy; and (iii) the dur-
ability of the response to lamivudine following withdrawal of
therapy in patients who have not developed lamivudine
resistance after 2 years of treatment.
METHODS
Patients
Consecutive Chinese adult patients with e-CHB treated with
lamivudine at the Hepatology Clinic of the Toronto General
Hospital between January 1999 and December 2001 were
reviewed. Only patients who met the following criteria
were included: hepatitis B surface antigen (HBsAg) positive,
HBeAg negative, HBe antibody (anti-HBe) positive, detect-
able serum HBV DNA by hybrid capture assay, and alanine
aminotransferase (ALT) >1.5 · upper limit of normal
(ULN, 40 IU/L), on two separate occasions during the
6-month period prior to the start of therapy. Patients were
excluded if they were coinfected with hepatitis C virus
(HCV), hepatitis D virus (HDV) and/or human immunode-
ficiency virus (HIV). All patients underwent a liver biopsy
prior to starting lamivudine therapy as per the usual
practice at the institution. Inflammation and fibrosis were
separately graded on a scale of 0–4 [25]. All patients who
received lamivudine therapy for e-CHB during the study
period met eligibility criteria and were included in this
analysis.
Definitions
Virological response was defined as undetectable serum HBV
DNA by PCR assay. Biochemical response was defined as de-
crease of ALT to normal range. Genotypic resistance (GR) was
defined as detection of rtM204V/I mutation. Virological
breakthrough was defined as reappearance of HBV DNA by
PCR during treatment after initial disappearance using PCR
assay. Biochemical breakthrough was defined as abnormal
ALT during treatment after initial normalization. Virological
relapse after treatment withdrawal was defined as reappear-
ance of HBV DNA by PCR assay. Clinical relapse after treat-
ment withdrawal was defined as detection of HBV DNA by
hybrid capture assay and ALT >1.5 · ULN.
Treatment protocol
All patients received lamivudine 100 mg orally daily. All
patients were evaluated at monthly intervals for 3 months
and thereafter at 3-monthly intervals. At each visit, patients
were screened for medication side-effects and tests for liver
chemistries, complete blood count, prothrombin time (INR:
international normalized ratio) hepatitis B serology and HBV
DNA were performed. In addition, extra sera were collected
at each visit and subsequently retrieved for HBV DNA testing
by PCR assay and for the detection of lamivudine resistance
mutations. Pretreatment samples were also tested for HBV
genotype. Serial samples prior to treatment and every
3–6 months thereafter were tested for precore, core
promoter and polymerase gene mutations.
Treatment was withdrawn in patients who had unde-
tectable HBV DNA by PCR and normal ALT on at least three
consecutive occasions during the second year of therapy and
at month 24. These patients were monitored monthly for
3 months, 3-monthly for the remainder of the year, and
thereafter every 6 months. Patients who had clinical relapse
after treatment withdrawal were restarted on lamivudine
100 mg orally daily.
HBV assays
Serum HBV DNA levels were determined using the Digene
Hybrid Capture II assay (Digene Corporation, Gaithersburg,
MD, USA) which has a lower limit of detection of
1.4 · 105 copies/mL or 0.5 pg/mL as well as the Cobas
Amplicor HBV Monitor assay (Roche Molecular Diagnostics,
Chatsworth, CA, USA) which has a lower limit of detection of
200 copies/mL [26]. HBV genotype, precore and core pro-
moter mutations as well as lamivudine-resistant HBV po-
lymerase gene mutations were detected by PCR and direct
sequencing [22].
Statistical analyses
Results were expressed either as mean ± standard deviation
or median and range. A database was created using Excel
(Microsoft, Redmond, WA, USA) and analysed using the
SPSS statistics program (SPSS Inc, Chicago, IL, USA). Sta-
tistical analyses were performed using chi-square and Fish-
er’s exact test for categorical variables. The student’s t-tests
were used for continuous variables. Rates of GR, virological
relapse and clinical relapse were estimated using the Kaplan–
Meier method. Results were considered statistically signifi-
cant at P < 0.05.
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RESULTS
Baseline demographic and virological data
Baseline demographic, clinical and virological data are
shown in Table 1. Data on 50 patients who have com-
pleted at least 1 year of therapy are included in this re-
port. Of these, 37 (74%) patients have completed 2 years
of therapy; while the remaining 13 patients were receiving
the second year of treatment. All patients were ethnically
Chinese, the mean age was 45.1 ± 10.3 years, and 40
(80%) were men. Fourteen (28%) patients had evidence of
cirrhosis on biopsy. The median pretreatment ALT was
93 IU/L. The median HBV DNA level was 1.1 · 107 cop-
ies/mL. All patients had HBV genotype C (78%) or B
(22%), none had genotype D. Precore stop codon mutation
with or without core promoter mutation was found in 27
(54%) patients. None of the patients had previously re-
ceived interferon or other antiviral therapy for chronic
hepatitis B. The mean duration of continuous lamivudine
therapy was 32.6 ± 13.0 months, as some of the patients
who developed GR were continued on treatment beyond
24 months.
Biochemical response
The percentage of patients with biochemical response at
different time points is illustrated in Fig. 1. Normalization of
ALT was observed in 74% patients at month 6 but decreased
to 71% at month 12 and 66% at month 24.
Virological response
The percentage of patientswith undetectable serumHBVDNA
using hybrid capture and PCR assays is shown in Fig. 2. At
month 6, HBV DNA became undetectable using hybrid
capture assay in all patients and in all but three patients (94%)
using PCR assay. With the emergence of lamivudine-resistant
mutations, the percentage of patients with virological
response declined. HBV DNA remained undetectable at
months 12, 18 and 24 using hybrid capture and PCR assays
in 92% and 88%, 90% and 78%, 86% and 74% patients,
respectively. No patient lost HBsAg during the study.
Genotypic resistance
Genotypic resistance to lamivudine was detected in nine
patients (18%) before month 24 of treatment, with a meanTable 1 Baseline characteristics of patients
No. of patients 50
Gender M:F 40:10
Mean age (years) ± SD 45.1 ± 10.3
Median ALT/ULN (range) 2.3 (0.8–24.9)
Patients with ALT >5 · ULN (%) 9 (18)




No. (%) of patients with cirrhosis 14 (28)
Median (range) inflammatory
score (max ¼ 4)
2 (1–3)
Median (range) fibrosis score (max ¼ 4) 3 (1–4)
HBV genotype – no. (%)
Genotype B 11 (22)
Genotype C 39 (78)
Precore/core promoter variant – no. (%)
Precore variant only 8 (16)
Core promoter variant only 21 (42)
Precore and core promoter mutations 19 (38)
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Fig. 1 Percentage of patients with biochemical response at
various time-points during the first 2 years of treatment
Biochemical response was defined as a decrease of ALT to
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Fig. 2 Percentage of patients with virological response at
various time-points during the first 2 years of treatment
Virological response as determined by undetectable serum
HBV DNA using hybrid capture (<5 pg/mL) and PCR assays
(<200 copies/mL).
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time to detection of 13.7 ± 6.2 months. The cumulative
rates of GR at months 12 and 24 were 15% and 25%,
respectively (see Fig. 3). Three patients had a combination of
rtL180M and rtM204V mutations, two had a combination of
rtL180M and rtM204I mutations, while four had an isolated
rtM204I mutation. There was no difference in age, gender,
pretreatment ALT, HBV DNA, liver histology, HBV genotype,
precore or core promoter sequence between the patients with
and without GR.
The nine patients with GR remained on lamivudine
treatment for 20.1 ± 11.0 months after the first detection of
lamivudine-resistant mutations. All patients had detectable
HBV DNA by PCR, six (67%) patients also had detectable
serum HBV DNA by hybrid capture assay. Biochemical
breakthrough occurred in seven (78%) patients. Four pa-
tients (44%) had ALT flares >5 · ULN, two patients (22%)
also had an increase in bilirubin level. One (11%) patient
developed hepatic decompensation with ascites 12 months
after virological breakthrough. This patient had cirrhosis at
baseline and a flare in ALT up to 3 · ULN prior to hepatic
decompensation. Despite receiving adefovir and achieving
undetectable HBV DNA by PCR, he continued to deteriorate
and received an orthotopic liver transplant 15 months after
virological breakthrough. An additional four patients with
GR had been started on adefovir, the remaining four patients
remained stable and were evaluated for adefovir treatment.
Three (33%) of the nine patients with GR reverted to HBeAg
positivity. In two patients, the reversion was transient, while
the third patient remained HBeAg positive for 16 months.
The third patient, who remained HBeAg positive, reverted
from precore stop codon mutation to wild-type precore se-
quence. Reappearance of HBeAg was not observed in any of
the patients who did not have GR, but reversion from pre-
core stop codon mutation to wild-type precore sequence was
observed in two of 41 (5%) patients who did not have GR.
Treatment withdrawal and post-treatment relapse
Twenty-seven of 37 (73%) patients who completed
24 months lamivudine treatment fulfilled criteria for treat-
ment withdrawal. Twenty-three (85%) patients have been
followed for a minimum of 6 months and 20 (74%) patients
for more than 12 months after treatment withdrawal.
Twelve (44%) patients had evidence of virological relapse,
and seven (26%) had clinical relapse. HBV DNA in those
who experienced clinical relapse ranged from 1.4 · 106 to
5.6 · 108 copies/mL. The cumulative rates of clinical and
virological relapse are illustrated in Fig. 4. The probability of
clinical and virological relapse 6, 12 and 18 months after
treatment withdrawal were 12% and 30%, 18% and 50%,
and 30 and 50%, respectively. The median time to virolo-
gical relapse was 4.5 months (range 3–9 months), while the
median time to clinical relapse was 12 months (range
3–27 months). All patients with clinical relapse were men
and six patients (86%) were infected with HBV genotype C
(see Table 2). Patients with clinical relapse have been fol-
lowed for a median of 27 months (range 15–36 months)
after treatment withdrawal and none of these patients has
experienced an increase in total bilirubin or evidence of
hepatic decompensation. All but one patient with clinical
relapse have responded to re-treatment with lamivudine.
The median duration of re-treatment was 15 months (range
3–33 months).
DISCUSSION
This is the first report of a 2-year course of lamivudine
treatment in Asian patients with e-CHB. Although there is
extensive literature on the efficacy of lamivudine treatment
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Fig. 3 Cumulative rates of genotypic resistance (GR) during
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Fig. 4 Cumulative rates of virological (solid line) and clin-
ical relapse (dashed line) after treatment withdrawal. Viro-
logical relapse was defined as reappearance of HBV DNA by
PCR assay. Clinical relapse was defined as detection of HBV
DNA by hybrid capture assay and ALT >1.5 · ULN.
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response to lamivudine therapy in Asian patients with e-CHB
may be different because of differences in virological factors.
Thus, while studies of Greek and Italian patients with e-CHB
found that almost all patients had HBV genotype D and
precore stop codon mutation, none of the patients in our
study had genotype D and only 54% had precore stop codon
mutation.
Despite these differences, we demonstrated that lamivu-
dine was effective in the treatment of e-CHB in Chinese pa-
tients. The initial response rate was comparable with or even
better than that reported in other trials with 88% and 92%
achieving undetectable HBV DNA by PCR and hybrid cap-
ture assay at month 12 compared with 60–70% in studies of
European patients [16–20]. As seen in other studies, resist-
ant mutants emerge with extended duration of treatment.
Thus, at month 24, virological response and biochemical
response decreased to 74% and 66%, respectively. Nine
(18%) patients developed GR before month 24, with esti-
mated cumulative rates of GR of 15% and 25% after 1 and
2 years of treatment, respectively. These rates of resistance
appeared to be lower than that reported among European
patients [18–20,22]. Additional studies with larger numbers
of patients are needed to confirm if the rate of resistance to
lamivudine in Chinese patients with e-CHB is indeed lower.
Because of the small number of patients in this study, we
were not able to identify factors associated with the devel-
opment of GR.
Although the rate of GR was low, most (78%) patients
with GR had biochemical breakthrough. In addition, one
patient with GR developed hepatic decompensation and
ultimately required a liver transplant despite the addition of
adefovir therapy. The high rate of biochemical relapse after
virological breakthrough is similar to that observed among
Greek patients [24]. In view of the potential adverse conse-
quence of lamivudine resistance, it is important to determine
if treatment withdrawal is possible in selected patients. Pre-
vious studies in European patients showed a high relapse
rate when treatment was withdrawn in all patients after
12 months [16]. In our study, treatment was withdrawn
only in patients who achieved undetectable HBV DNA by
PCR on at least three occasions during the second year of
treatment. Using these criteria, 73% of patients who com-
pleted 24 months of treatment were eligible for treatment
withdrawal.
Despite the stringent criteria, a high rate of virological
relapse (50% had detectable serum HBV DNA by PCR assay
at 18 months) was observed after treatment withdrawal.
Virological relapse may precede clinical relapse. However,
not all patients with virological relapse developed clinical
relapse. The estimated rate of clinical relapse 18 months
after treatment withdrawal was only 30%. We used the
same criteria for initial treatment as definition for clinical
relapse because it is unclear if very low levels of HBV DNA
detectable only by PCR assay are clinically significant and
warrant re-treatment. We acknowledge that the duration of
post-treatment follow-up is relatively short, and it is con-
ceivable that with time, more patients may experience
virological and ultimately clinical relapse. However, all epi-
sodes of virological relapse occurred within 12 months of
treatment withdrawal while clinical relapse was delayed by
Table 2 Comparison of patients with and without clinical relapse after treatment withdrawal
Clinical relapse No clinical relapse P
No. of patients 7 20 –
Gender M:F 7:0 15:5 0.34
Mean age in years ± SD 41.7 ± 14.8 44.9 ± 8.9 0.68
Genotype B:C 1:6 3:17 0.98
Core promoter variant only (%) 5 (71) 9(45) 0.31
Precore variant only (%) 1 (14) 4(20) 0.85
Double variants (%) 1 (14) 6(30) 0.57
Wild-type precore/core promoter sequence 0 (0) 1 (5) 0.85
Median (range) pretreatment HBV DNA in log10 copies/mL 7.5 (6.8–8.5) 7.0 (6.2–8.8) 0.19
Median (range) pretreatment ALT/ULN 2.6 (1.5–11.9) 2.1 (1.4–7.3) 0.34
Patients with pretreatment ALT >5 · ULN (%) 2 (29) 3 (15) 0.61
Liver histology
No. (%) of patients with cirrhosis 3 (43) 4(20) 0.40
Median (range) inflammatory score (max ¼ 4) 2 (1–2) 2 (1–3) 0.68
Median (range) fibrosis score (max ¼ 4) 3 (1–4) 3 (1–4) 0.53
Median (range) ALT/ULN at month 24 0.95 (0.4–1.1) 0.55 (0.2–1.4) 0.43
Median (range) consolidation therapy in months* 9 (6–18) 12 (6–18) 0.07
Median time to clinical relapse in months (range) 12 (3–27) N/A –
Median follow-up post treatment in months (range) 27 (15–36) 15 (0–27) 0.001
*Duration of treatment from the time HBV DNA first became undetectable by PCR.
 2004 Blackwell Publishing Ltd, Journal of Viral Hepatitis, 11, 432–438
436 S. K. Fung et al.
6 months. As 74% of the patients had at least 12 months
and 50% had at least 18 months of post-treatment follow-
up, our data suggest that a sustained response can be
achieved in selected patients with longer duration of treat-
ment. Another limitation of our study is the lack of follow-up
liver biopsies. Patients with virological relapse may experi-
ence progressive liver disease, even if the ALT remains below
1.5 · ULN. Analysis of the clinical and laboratory parame-
ters at baseline and month 24 found that all patients who
relapsed were men with genotype C. These findings, if con-
firmed, can be used to further refine the criteria for treatment
withdrawal in future patients.
In summary, this report of lamivudine treatment of e-CHB
in Chinese patients demonstrated some fundamental differ-
ences in viral factors between Chinese and European patients
with e-CHB. Nevertheless, initial virological and biochemical
responses were comparable or even better than those
reported in studies from Europe. GR appeared to occur at a
lower rate, but almost all patients with virological break-
through developed biochemical breakthrough. Lamivudine
may be safely withdrawn in selected patients, who achieve
adequate viral suppression after 2 years of treatment.
However, close follow-up after treatment withdrawal is re-
quired to detect clinical relapse. Although virological relapse
was relatively common, not all patients developed clinical
relapse. Longer follow-up of a larger number of patients is
needed to confirm our findings, to identify factors that are
predictive of relapse, and to further refine the criteria for
lamivudine withdrawal in patients with e-CHB.
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